vimarsana.com

Latest Breaking News On - Mlifidase - Page 1 : vimarsana.com

Hansa Biopharma AB: Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation

LUND, Sweden, June 1, 2023 /PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained

Region flamandeStephanie kenneyHansa biopharmaPrnewswire hansa biopharmaDirk kuypersKlaus sindahlDepartment of nephrologyUniversity hospitals leuvenEuropean unionEuropean medicines agency ema priorityRenal transplantation programVp global corporate affairsEuropean medicines agencyNasdaq stockholmHuman leukocyte antigensProduct characteristics

Hansa Biopharma AB: Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

LUND, Sweden, May 30, 2023 /PRNewswire/ Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with

United kingdomKlaus sindahlPrnewswire hansa biopharmaHansa biopharmaStephanie kenneyVp global corporate affairsEuropean medicinal agencyInternational coordinating investigatorProfessor of nephrology at lund universityUniversity hospitalLund universityGefallene big techs

vimarsana © 2020. All Rights Reserved.